Viral Vector Purification / Virus Purification Products Markets, 2030: Focus on Kit, Prepacked Column, Resin, Cassette, Filter Plate, Capsule, Reagent and Others

·8 min read

DUBLIN, Oct. 13, 2020 /PRNewswire/ -- The "Viral Vector Purification / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The Viral Vector Purification / Virus Purification Products Market 2020-2030' report features an extensive study of various products available for viral vector purification, in addition to the current market landscape and future potential of product developers.

Overview

Since the approval and launch of cell and gene therapy products, such as Zolgensma (2019), ZYNTEGLO (2019), Luxturna (2017), KYMRIAH (2017) and YESCARTA (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019.

Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in this domain. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings.

Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.

A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging.

Scope of the Report

An overview of the current market landscape of companies providing products for purification of viruses / viral vectors, using different techniques, such as chromatography, centrifugation and filtration. It features information on the type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration), scale of operation (lab-scale, clinical and commercial), type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others) and details on other physical and operational parameters of the product (such as matrix, pore size, volume of bed, flow rate, operating pressure, working temperature, pH, filtration area and process time).

In addition, the chapter includes information on the purification product developers, including details on the year of establishment, company size and location of headquarters. Elaborate profiles of key players, including an overview of the company, product portfolio (viral vector purification products), recent developments and an informed future outlook.

An analysis evaluating the potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on several parameters, such as type of viral vector, developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline.

A clinical trial analysis of completed, ongoing and planned studies of various viral vector-based cell therapies, gene therapies and vaccines (approved / under development). It features detailed analyses of clinical studies of different viral-vector based therapies on the basis of their registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor/collaborator, geographical location, number of patients enrolled and key players.

An informed estimate of the annual clinical and commercial demand (in terms of number of patients) for viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength. Further, the demand has been segregated on the basis of type of viral vector, type of therapy, therapeutic are and geographical location.
A case study on tangential flow filtration (TFF), highlighting the role, advantages and disadvantages of the technique for purification of viral vectors; the chapter features details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area.

A case study featuring the viral vector manufacturers providing commercial scale production, highlighting details on their year of establishment, company size, type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), and location of headquarters and manufacturing facilities.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for viral vector purification product developers, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030.

Companies Mentioned

  • 4D Molecular Therapeutics

  • Abbott

  • Abeona Therapeutics

  • Actus Therapeutics

  • Adaptimmune Therapeutics

  • Addgene

  • Advanced BioScience Laboratories

  • Advantagene

  • Advaxis

  • Advent

  • Adverum Biotechnologies

  • Agilent Technologies

  • Allergan

  • Allife Medical Science and Technology

  • Allogene Therapeutics

  • AlphaVax

  • ALSTEMlstem

  • Altor BioScience

  • American Gene Technologies

  • Amgen

  • Amicus Therapeutics

  • AMSBIO

  • Anaeropharma Science

  • Angionetics

  • apceth Biopharma

  • Apic Bio

  • Applied Biological Materials

  • Applied Genetic Technologies Corporation

  • Applied Viromics

  • Arthrogen

  • Aruvant Sciences

  • Asklepios BioPharmaceutical

  • Atara Biotherapeutics

  • ATVIO Biotechnology

  • Audentes Therapeutics

  • Aurora Biopharma

  • Autolus

  • AVROBIO

  • Axovant

  • Batavia Biosciences

  • Bayer

  • Baylor College of Medicine

  • Beijing Biohealthcare Biotechnology

  • Beijing Doing Biomedical

  • Beijing Immunochina Medical Science & Technology

  • Beijing Mario Biotech

  • Beijing Sanwater Biological Technology

  • Bellicum Pharmaceuticals

  • BIA Separations

  • Bioceltech Therapeutics

  • Biogen

  • BioMarin Pharmaceutical

  • BioNTech Innovative Manufacturing Services

  • Bio-Rad

  • BioReliance

  • Bioverativ

  • Biovian

  • BioVision

  • Blue Sky BioServices

  • bluebird bio

  • Brammer Bio

  • Bristol-Myers Squibb

  • Carina Biotech

  • CARsgen Therapeutics

  • Castle Creek Pharmaceuticals

  • Celgene

  • Cell Biolabs

  • Cellectis

  • CELLforCURE

  • CellGenTech

  • Cellular Biomedicine

  • Celonic

  • Celyad

  • Centre for Process Innovation

  • CEVEC Pharmaceuticals

  • China Immunotech

  • Clean Cells

  • Cobra Biologics

  • Cold Genesys

  • Creative Biogene

  • Creative Biolabs

  • CRISPR Therapeutics

  • Cytiva

  • Cytovance Biologics

  • Daiichi Sankyo

  • DNAtrix

  • Editas Medicine

  • Emergent BioSolutions

  • Epeius Biotechnologies

  • Errant Gene Therapeutics

  • Esteve

  • ExcellGene

  • Fibrocell

  • FinVector

  • FIT Biotech

  • FKD Therapies

  • Flash Therapeutics

  • Flexion Therapeutics

  • Formula Pharmaceuticals

  • Fosun Pharma

  • Freeline Therapeutics

  • FUJIFILM Diosynth Biotechnologies

  • GE Healthcare

  • GEG Tech

  • Gene Biotherapeutics

  • GeneCure Biotechnologies

  • GeneDetect

  • Genelux Corporation

  • Genethon

  • Genezen Laboratories

  • GenIbet Biopharmaceuticals

  • GenSight Biologics

  • GenVec

  • GlaxoSmithKline

  • Gracell Biotechnologies

  • Guangdong Xiangxue Precision Medical Technology

  • Guangdong Zhaotai InVivo Biomedicine

  • Guangzhou Anjie Biomedical Technology

  • Guangzhou Double Bioproducts

  • Guangzhou FineImmune Biotechnology

  • Guangzhou YiYang Biological Technology

  • Gyroscope Therapeutics

  • Hebei Senlang Biotechnology

  • Hemera Biosciences

  • Henan Hualong Biotechnology Company

  • Herantis Pharma

  • Holostem Terapie Avanzate

  • Homology Medicines

  • Horama

  • Hrain Biotechnology

  • Hunan Zhaotai Yongren Biotech

  • Hunan Zhaotai Yongren Medical Innovation

  • iCAR Bio Therapeutics

  • iCarTAB BioMed

  • iCell Gene Therapeutics

  • ID Pharma

  • Immatics

  • Immunocore

  • Innovative Cellular Therapeutics

  • Janssen Pharmaceuticals

  • Juno Therapeutics

  • JW Therapeutics

  • KAEDI

  • Kite Pharma

  • Kolon TissueGene

  • Krystal Biotech

  • Kuur Therapeutics

  • Lentigen Technology

  • Leucid Bio

  • Lion TCR

  • Lokon Pharma

  • Lonza

  • Lysogene

  • Marino Biotechnology

  • Marsala Biotech

  • Mayflower Bioscience

  • Medigene

  • MedImmune

  • MeiraGTx

  • Merck

  • Milo Biotechnology

  • Miltenyi Biotec

  • MingJu Therapeutics

  • MolMed

  • Momotaro-Gene

  • MultiVir

  • Mustang Bio

  • Myonexus Therapeutics

  • Nanjing Legend Biotech

  • NEC

  • Neuralgene

  • Neurocrine Biosciences

  • Nightstar Therapeutics

  • Nikon CeLL innovation

  • Norgen Biotek

  • Novartis

  • Novasep

  • Oncolys BioPharma

  • ORCA Therapeutics

  • Orchard Therapeutics

  • Oxford BioMedica

  • Oxford Genetics

  • OZ Biosciences

  • Pall Biotech

  • Paragon Gene Therapy

  • PeriphaGen

  • PersonGen BioTherapeutics

  • Pfizer

  • Pinze Lifetechnology

  • Precigen

  • Precision BioSciences

  • ProBioGen

  • ProMab Biotechnologies

  • PsiOxus Therapeutics

  • PTC Therapeutics

  • Regeneron Pharmaceuticals

  • REGENXBIO

  • ReiThera

  • Renova Therapeutics

  • Rocket Pharmaceuticals

  • Rubius Therapeutics

  • SAB Technology

  • Sangamo Therapeutics

  • Sanofi

  • Sarepta Therapeutics

  • Sartorius

  • Servier

  • Shanghai Bioray Laboratory

  • Shanghai GeneChem

  • Shanghai Longyao Biotechnology

  • Shanghai Sinobioway Sunterra Biotechnology

  • Shanghai Sunway Biotech

  • Shanghai Unicar-Therapy Bio-medicine Technology

  • Shenzhen BinDeBio

  • Shenzhen SiBiono GeneTech

  • Shionogi

  • SignaGen Laboratories

  • SillaJen

  • Sinobioway Cell Therapy

  • SIRION Biotech

  • Solid Biosciences

  • Sorrento Therapeutics

  • SOTIO

  • Spark Therapeutics

  • System Biosciences

  • Takara Bio

  • Takeda

  • Targovax

  • Tasly Biopharmaceuticals

  • TCR2 Therapeutics

  • TCRCure Biopharma

  • The Beijing Pregene Science and Technology

  • The Pregene (ShenZhen) Biotechnology

  • TheraBiologics

  • Theravectys

  • Thermo Fisher Scientific

  • Tianjin Mycure Medical Technology

  • Timmune

  • Tmunity Therapeutics

  • Tocagen

  • Transgene

  • Ultragenyx Pharmaceutical

  • Union Stem Cell & Gene Engineering

  • uniQure

  • Unum Therapeutics

  • Vascular Biogenics

  • VCN Biosciences

  • Vector Biolabs

  • Vertex Pharmaceuticals

  • Vessl

  • Vibalogics

  • Vigene Biosciences

  • ViralGEN

  • Virapur

  • ViraQuest

  • Virovek

  • Virttu Biologics

  • VIVEbiotech

  • Voyager Therapeutics

  • Wuhan Sian Medical Technology

  • WuXi AppTec

  • Wyvern Pharmaceuticals

  • Xiangxue Life Sciences

  • Xiangxue Pharmaceutical

  • XyloCor Therapeutics

  • Yake Biotechnology

  • Yposkesi

  • Ziopharm Oncology

For more information about this report visit https://www.researchandmarkets.com/r/7vgthw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/viral-vector-purification--virus-purification-products-markets-2030-focus-on-kit-prepacked-column-resin-cassette-filter-plate-capsule-reagent-and-others-301150966.html

SOURCE Research and Markets

Recommended Stories

  • ‘We don’t want to wait on study’: Biden adviser vows to start acting ‘now’ on systemic racism

    ‘We have to start breaking down systemic racism and barriers that have held people of colour back and especially African Americans’

  • Rooster kills Indian man during banned cockfight

    A man was killed by a rooster with a blade tied to its leg during an illegal cockfight in southern India, police said, bringing focus on a practice that continues in some Indian states despite a decades-old ban. The rooster, with a 3-inch knife tied to its leg, fluttered in panic and slashed its owner, 45-year-old Thangulla Satish, in his groin last week, police inspector B. Jeevan said Sunday. According to Jeevan, Satish was injured while he prepared the rooster for a fight.

  • U.S. envoy visits Kabul looking for ways to speed up Afghan peace process

    The U.S. special envoy to Afghanistan, Zalmay Khalilzad held discussions on Monday with a senior Afghan official in Kabul over ways to accelerate the peace process, before heading to Qatar, where negotiations with Taliban representatives are ongoing. U.S.-brokered peace talks between the Afghan government and the militant group began in September but progress has slowed and violence has risen, while there is also uncertainty over whether international forces will pull out troops by May as originally planned. The State Department said in a statement on Sunday that Khalilzad and his team were visiting Kabul and Qatar.

  • New Orleans Archdiocese Asks Catholics to Avoid Johnson & Johnson COVID Vaccine

    The Catholic Archdiocese of New Orleans is asking Catholics to avoid the recently-approved Johnson & Johnson COVID-19 vaccine, which it says is “morally compromised” by its “extensive use of abortion-derived cell lines.” In a statement on Friday, the archdiocese noted that while deciding whether to receive the vaccine is an individual choice, that “the latest vaccine from Janssen/Johnson & Johnson is morally compromised as it uses the abortion-derived cell line in development and production of the vaccine as well as the testing.” While a number of COVID-19 vaccine manufacturers have used cells originally derived from an aborted fetus in the 1970s, the archdiocese argues that Johnson & Johnson “extensive use” is worse than that of Moderna and Pfizer-BioNTech vaccines, which used the cells lines only to test their vaccines, according to Religion News Service. This makes the “connection to abortion … extremely remote,” in the Moderna and Pfizer vaccines, the statement argues, recommending that Catholics choose one of those instead, if provided a choice. While the archdiocese claims the decision is in line with guidance from the Vatican, the U.S. Conference of Catholic Bishops and the National Catholic Bioethics Center, none of the three have issued statements denouncing the new vaccine. In December, the Vatican issued general guidelines regarding vaccines in which the Holy See said it was “morally acceptable” for Catholics to receive shots that used the HEK293 cells for research. While the HEK293 cells are reportedly originated from an aborted fetus from the 1970s, ethicists have said that the cells and similar cell lines are clones and not the original fetal tissue. The Vatican has made the Pfizer-BioNTech vaccine available for all Vatican City residents. Pope Francis reportedly received the shot in January. The Archdiocese of New Orleans’ statement comes after leaders of the USCCB and leaders from other religious organizations sent a letter to the commissioner of the U.S. Food and Drug Administration last spring regarding ethical concerns over the COVID-19 vaccines. “We are aware that, among the dozens of vaccines currently in development, some are being produced using old cell lines that were created from the cells of aborted babies,” the letter read. “For example, Janssen Pharmaceuticals, Inc. has a substantial contract from the U.S. Department of Health and Human Services (HHS) and is working on a vaccine that is being produced using one of these ethically problematic cell lines.” However, a USCCB memo written by Bishop Kevin C. Rhoades of Fort Wayne-South Bend, who chairs the USCCB’s Committee on Doctrine, and Archbishop Joseph F. Naumann of Kansas City, who chairs the organization’s Committee on Pro-Life Activities, argued that the vaccines are moral.

  • Trump reportedly quietly got his COVID-19 vaccine in January

    Former President Donald Trump never ended up getting his COVID-19 vaccine publicly before he left office — but he reportedly did so off camera. At the Conservative Political Action Conference on Sunday, Trump encouraged supporters to get their COVID-19 vaccine, renewing questions over whether the former president has done so himself. Numerous officials, including former Vice President Mike Pence, got vaccinated on live television as part of an effort to demonstrate to Americans that it's safe. Trump never did so. But The New York Times' Maggie Haberman on Monday reported that according to an adviser, Trump actually did get vaccinated at the White House in January, as did former first lady Melania Trump, even though they didn't say so publicly at the time. The report was confirmed by CNN and Axios. The Los Angeles Times' Chris Megerian noted it was "noteworthy that the former president didn't do this publicly to boost public confidence in the vaccine." Trump yesterday, at CPAC, said for the first time that "everyone" should get the coronavirus vaccine developed while he was in office. An adviser tells me both Trump and Melania Trump got vaccinated at the White House in January. — Maggie Haberman (@maggieNYT) March 1, 2021 In December, then-Surgeon General Jerome Adams said Trump had a "medical reason" for not getting the vaccine yet, as he "received monoclonal antibodies" when he had COVID-19, "and that is actually one scenario where we tell people, 'Maybe you should hold off on getting the vaccine, talk to your health provider to find out the right time.'" CNN's Betsy Klein notes the White House had repeatedly declined to comment when asked if Trump had gotten the vaccine or intended to do so, even "as recently as January 18." After Trump's CPAC speech, The Washington Post's Aaron Blake flagged his comments encouraging his supporters to get vaccinated as "perhaps the most significant thing he said," noting this was "something he avoided forcefully advocating for when he actually commanded the most powerful office in the world." More stories from theweek.comTrump is back. Did anyone miss him?Trump still has the Republican Party by the throatMost awkward awards show ever?

  • The White House says it never wants an assassination like Khashoggi's again, but won't punish MBS for ordering the killing

    Biden's White House has essentially leaned on the importance of the diplomatic relationship with Saudi Arabia in defense of its actions.

  • Hilaria and Alec Baldwin welcome 6th baby together nearly 6 months after birthing their son Eduardo

    The baby was born nearly sixth months after Hilaria Baldwin gave birth to her son Eduardo "Edu" Pao Lucas.

  • A man who refused to wear a mask at a high-school basketball game killed a police officer following a confrontation, authorities say

    The police officer, Martinus Mitchum, was fatally shot while trying to break up an altercation between a man and a school employee over face masks.

  • DeSantis joins GOP governors, says $16 billion in federal relief to Florida is unfair

    The $1.9 trillion COVID-19 federal relief package would mean $16 billion in aid to Florida. $10 billion to the state and $6 billion to cities and counties. The governor says it’s unfair.

  • Why Johnson & Johnson's COVID-19 vaccine is probably the best shot

    Some people might prefer Johnson & Johnson's shot because it was tested on variants, has milder side effects, and is easier to get.

  • Canada vaccine committee advises against use of AstraZeneca COVID-19 shots for 65 years and above

    Canada's National Advisory Committee on Immunization released new guidelines on Monday that advise against vaccinating people who are 65 years and older with AstraZeneca's COVID-19 vaccine, citing lack of information about efficacy in that age group. The vaccine was authorized for people who are 18 and older by drug regulator Health Canada on Friday. Health Canada's decision noted that available clinical trial data was too limited to reliably estimate how well the vaccine worked in people 65 and older.

  • Senate Democrats prepare to advance the $1.9 trillion stimulus plan without a $15-an-hour minimum wage

    Democratic efforts to salvage the wage increase with a new tax plan collapsed over the weekend as Senate Democrats gear up to pass the stimulus bill.

  • Are your tires among the 440,000 across 9 brands that have just been recalled?

    Problems with tires made by Cooper and sold by eight other brands — sidewall problems in particular — caused two recalls of approximately 442,955 tires last week.

  • Alexandria Ocasio-Cortez shoots back at Ted Cruz, saying he treated storm-hit Texas as a 'layover' between trips to Cancun and CPAC

    "It appears Texas was just a layover stop for him between Cancun and Orlando to drop a pack of water into someone's trunk," Ocasio-Cortez said.

  • Trump privately received the coronavirus vaccine while he was president in January

    Trump and former first lady Melania Trump got the COVID-19 vaccine at the White House, according to multiple reports.

  • New video shows US forces getting hammered by a barrage of Iranian missiles after Trump had a top general killed

    "Just always know in your heart that I love you, OK? Bye, buddy," an Army soldier, believing he was going to die, told his son in a video.

  • NASCAR at Homestead live updates: William Byron takes checkered flag

    The NASCAR Cup Series hits its first intermediate track of the year at Homestead-Miami Speedway.

  • A former NFL player who was missing for several days has been found dead in Florida

    Louis Nix's family confirmed his death after officials found his vehicle in a retention pond near his Jacksonville apartment on Saturday.

  • Meghan Markle, Prince Harry discuss ‘shocking things’ in interview, Oprah says

    Oprah Winfrey has seen just about everything in her career but even she appeared stunned by the “shocking things” Meghan Markle and Prince Harry revealed in their upcoming sit down with her. Sunday, Winfrey previewed a teaser of her long-awaited Oprah with Meghan and Harry: A CBS Primetime Special, on CBS during that evening’s broadcast of 60 Minutes and was candid from the jump. “I just want to make it clear to everybody there is no subject that’s off-limits,” Winfrey said in the clip.

  • Prince Harry Tells Oprah He Left the Royals Because He Feared Meghan Markle Would Suffer Like Princess Diana

    JOHNNY EGGITT / Getty ImagesPrince Harry has told Oprah Winfrey that he decided to step back from the British royal family because he was fearful of “history repeating itself,” apparently referring to the tragic story of his mother, Diana, who died at 36 in a car crash in Paris while being pursued by paparazzi.Harry, who is now 36 himself, made the remarks in his interview with CBS which will be screened on March 7. Two advance clips from the special were released on Monday morning.CBS Presents Oprah with Meghan and Harry: A Primetime Special in one week. #OprahMeghanHarry pic.twitter.com/WCyoHDMCaP— CBS (@CBS) March 1, 2021 In one of the new Oprah clips, Harry was seated next to Meghan, 39, with whom he is expecting a second child. As he held her hand, he reflected on the ordeal his mother went through when she left the royal family.“I’m just really relieved and happy to be sitting here talking to you with my wife by my side,” he said. “Because I can’t imagine what it must have been like for her [Diana], going through this process by herself all those years ago.“It’s been unbelievably tough for the two of us, but at least we had each other.”In a second clip, Winfrey said to Meghan that no subject was off-limits and at one point tells the couple, “You have said some pretty shocking things here.” Oprah also asks Meghan if she was “silent or silenced.”Winfrey appeared to reference a comment made by Meghan when she said that the trolling she received was “almost unsurvivable.”The conversation was flagged as the first TV interview to be given by the couple since they made California their home last year, but Harry rather spoiled Winfrey’s exclusive when he taped an open-air bus-top interview with another old friend, James Corden, which was broadcast last week. Prince Harry Tells Friend James Corden He Left the Royal Family Because It Was Destroying His Mental HealthIn that interview, Harry said he was more concerned about the intrusions of the media into his family’s life than the Netflix show The Crown, which he said was “obviously fiction.” His friend Corden did not ask whether Harry’s sympathetic attitude to the show was influenced by the reported $100 million fee the couple received from Netflix to produce content.Harry told Corden that the British press created a “difficult environment” that was destroying his mental health but insisted he “didn’t walk away” from the royal family. “It was stepping back rather than stepping down.”He said, “I did what any husband, what any father would do. It’s like, ‘I need to get my family out of here.’ But we never walked away.” He added, “I will never walk away. I will always be contributing.”The spate of interviews come after Buckingham Palace announced the couple would not be returning to their former roles as working members of the royal family.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.